1. Scrip
  2. >>Therapy Areas

Bayer/Ionis Advance Next-Generation Antithrombotic After Positive Clinical Results

And Bayer Sets Up Artificial Intelligence Center In The UK

 
• By John Davis

In a collaboration with Ionis Pharmaceuticals, Bayer is pressing ahead with Phase II clinical studies of an antisense molecule designed to reduce Factor XI production and prevent thrombosis.

Deep_Vein_Thrombosis
• Source: Shutterstock

An investigational antisense product, IONIS-FXI-LRx, is progressing into Phase II studies in a collaboration between Bayer AG and US biotech Ionis Pharmaceuticals Inc., the companies announced on 9 October.

The move follows positive clinical results with the product, Bayer noted. IONIS-FXI-LRx is designed to reduce the production of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.